The state of Illinois currently has 58 active clinical trials seeking participants for Diabetes research studies. These trials are conducted in various cities, including Chicago, Peoria, Springfield and Urbana.
Black Girls Move Physical Activity and Improving Dietary Intake Among Black Adolescent Daughters
Recruiting
Black Girls Move is a school-linked daughter/mother physical activity and dietary behavior program, with 9th and 10th grade students. This program is designed to prevent obesity in Black adolescent females and thus aligns with the NIH mission to enhance health, lengthen life, and reduce illness and disability. This project is relevant to public health because it holds the potential to reduce population health disparities impacted by structural racism.
Gender:
Female
Ages:
Between 12 years and 18 years
Trial Updated:
05/20/2024
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Adolescent Obesity, Diabetes Mellitus
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Recruiting
The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will lasts around 31 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/19/2024
Locations: Great Lakes Clinical Trials - Ravenswood, Chicago, Illinois
Conditions: Overweight or Obesity, CKD, Type 2 Diabetes
Promoting Preconception Care and Diabetes Self-Management Among Reproductive-Aged Women With Diabetes
Recruiting
This study is being done to investigate strategies that may improve patient's knowledge of type 2 diabetes during reproductive age and improve knowledge and engagement in self-care activities.
Gender:
Female
Ages:
Between 18 years and 44 years
Trial Updated:
05/13/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Diabetes Mellitus, Type 2, Electronic Health Record, Primary Health Care, Reproductive Behavior
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: University of Chicago Medicine, Chicago, Illinois +2 locations
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Dietary Supplementation on Body Fat Composition
Recruiting
The purpose of the current study is to examine the effects of a dietary supplement containing plant derived phenolics at two different dose levels in otherwise generally healthy adults with risk factors (high BMI at dyslipidemia and/or pre-diabetes) for body fat composition. The primary hypothesis is that supplementation with plant derived phenolics will decrease body fat composition compared to placebo.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/13/2024
Locations: Biofortis Research, Addison, Illinois
Conditions: Dyslipidemias, Pre-diabetes
A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
Recruiting
Researchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work properly, and type 1 diabetes. In people with type 1 diabetes, the body does not make enough of a hormone called insulin, resulting in high blood sugar levels that can cause damage to the kidneys. CKD often occurs together with or as a consequence of type 1 diabetes. The study treatment finerenone works by blocking certain proteins, called mineraloc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Northwestern University, Chicago, Illinois +1 locations
Conditions: Chronic Kidney Disease, Type 1 Diabetes Mellitus
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Recruiting
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine togethe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Cedar-Crosse Research Center, Chicago, Illinois +3 locations
Conditions: Type 2 Diabetes Mellitus
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
Recruiting
This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesit... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Evanston Premier Healthcare Research LLC, Skokie, Illinois
Conditions: Obesity, Diabetes Mellitus, Type 2
Evaluation of the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes on Insulin Therapy
Recruiting
The Revita® system is being investigated to assess the efficacy of DMR versus Sham on improvement in Glycemic, Hepatic and Cardiovascular endpoints for patients with Type 2 Diabetes who are inadequately controlled with insulin therapy. The purpose of this study is to demonstrate the efficacy and safety of the Fractyl DMR Procedure using the Revita® System compared to a sham. Subjects randomized to the DMR procedure will be followed per protocol till 48 weeks post treatment. Subjects in the Sham... Read More
Gender:
All
Ages:
Between 21 years and 70 years
Trial Updated:
05/10/2024
Locations: Northwestern Unviersity, Evanston, Illinois
Conditions: Type 2 Diabetes
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)
Recruiting
This is a randomized, parallel group, double-blind Phase 2 study that consists of 2 parts. In Part A the safety of the highest dose-level of frexalimab in adults (age range 18-35 y.o.) will be established. In Part B, a dose-finding study (adolescents and young adults, 12-21 y.o.) evaluating the safety and efficacy of 3 age-adjusted dose-levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment. The purpose of this study is to determine safety a... Read More
Gender:
All
Ages:
Between 12 years and 35 years
Trial Updated:
05/08/2024
Locations: NorthShore University HealthSystem Site Number : 8400007, Skokie, Illinois
Conditions: Type 1 Diabetes Mellitus
Mechanisms of Prediabetic States in Sleep Apnea
Recruiting
The purpose of this study is to better understand how sleep apnea contributes to the development of diabetes.
Gender:
All
Ages:
Between 20 years and 65 years
Trial Updated:
05/07/2024
Locations: University of Chicago, Chicago, Illinois
Conditions: Sleep Apnea, Pre-diabetes
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Recruiting
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either dr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/06/2024
Locations: Cedar-Crosse Research Center, Chicago, Illinois +3 locations
Conditions: Type 2 Diabetes